Trial Profile

A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 23 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Crizanlizumab (Primary) ; Nisevokitug (Primary) ; Rineterkib (Primary) ; Ruxolitinib (Primary) ; Sabatolimab (Primary) ; Siremadlin (Primary)
Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms ADORE
Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

23 Aug 2025 Status changed from completed to discontinued due to sponsors decision.
19 Sep 2024 Status changed from active, no longer recruiting to completed.
13 Sep 2024 This study has been Completed in Belgium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com